2023
Real-world treatment patterns, survival, health resource use and costs among Medicare beneficiaries with diffuse large B-cell lymphoma
Garg M, Puckett J, Kamal-Bahl S, Raut M, Ryland K, Doshi J, Huntington S. Real-world treatment patterns, survival, health resource use and costs among Medicare beneficiaries with diffuse large B-cell lymphoma. Future Oncology 2023, 20: 317-328. PMID: 38050764, DOI: 10.2217/fon-2023-0191.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaReal-world treatment patternsLarge B-cell lymphomaB-cell lymphomaTreatment patternsMedicare beneficiariesFirst-line treatmentFront-line treatmentHealthcare resource useHealth resource useElderly Medicare beneficiariesUnmet need existsOverall survivalR-CHOPMedicare patientsLater linesOlder adultsTreatmentPatientsLymphomaNeed existsSurvivalTwo-thirdsResource useSame periodA phase 2 trial of mosunetuzumab with lenalidomide augmentation as first-line therapy for follicular (FL) and marginal zone lymphoma (MZL).
Olszewski A, Huntington S, Ollila T, Pelcovits A, McMahon J, Yakirevich I, Sturtevant A, Chorzalska A, Morgan J, Dubielecka P. A phase 2 trial of mosunetuzumab with lenalidomide augmentation as first-line therapy for follicular (FL) and marginal zone lymphoma (MZL). Journal Of Clinical Oncology 2023, 41: tps7588-tps7588. DOI: 10.1200/jco.2023.41.16_suppl.tps7588.Peer-Reviewed Original ResearchMarginal zone lymphomaCytokine release syndromeFirst-line therapyCR rateT cell-engaging bispecific antibodiesFirst-line systemic therapyCytotoxic T cell responsesLow-dose lenalidomideComplete response rateFirst-line treatmentLines of therapyPhase 2 trialT-cell depletionT cell immunityT cell responsesHost immune environmentRate of progressionRates of toxicityNovel therapeutic approachesHigh-burden diseasesImmunosuppressive modalitiesRefractory FLRelease syndromeStable diseaseStudy therapy
2022
Treatment Patterns of Follicular Lymphoma in the United States: A Claims Analysis
Huntington S, Appukkuttan S, Wang W, Du Y, Hopson S, Babajanyan S. Treatment Patterns of Follicular Lymphoma in the United States: A Claims Analysis. Journal Of Health Economics And Outcomes Research 2022, 9: 115-122. PMID: 36348725, PMCID: PMC9603402, DOI: 10.36469/001c.38070.Peer-Reviewed Original ResearchLines of therapyFirst-line treatmentFollicular lymphomaTreatment patternsRituximab monotherapyCommon first-line treatmentReal-world treatment patternsFourth-line therapyOptimal treatment sequencingThird-line therapyDuration of therapyInitiation of treatmentCommon indolent lymphomaLine of treatmentNumber of patientsActive regimensRituximab therapyBaseline characteristicsMost patientsRetrospective cohortIBM MarketScanPrimary outcomeContemporary cohortIndolent lymphomaMedian timeTreatment Patterns of Follicular Lymphoma in the United States: A Claims Analysis
Huntington S, Appukkuttan S, Wang W, Du Y, Hopson S, Babajanyan S. Treatment Patterns of Follicular Lymphoma in the United States: A Claims Analysis. Journal Of Health Economics And Outcomes Research 2022, 115-122. DOI: 10.36469/jheor.2022.38070.Peer-Reviewed Original ResearchLines of therapyFirst-line treatmentFollicular lymphomaTreatment patternsRituximab monotherapyCommon first-line treatmentReal-world treatment patternsFourth-line therapyOptimal treatment sequencingThird-line therapyDuration of therapyInitiation of treatmentCommon indolent lymphomaLine of treatmentNumber of patientsActive regimensRituximab therapyBaseline characteristicsMost patientsRetrospective cohortIBM MarketScanPrimary outcomeContemporary cohortIndolent lymphomaMedian time
2020
Challenges and Opportunities in the Management of Diffuse Large B‐Cell Lymphoma in Older Patients
Di M, Huntington SF, Olszewski AJ. Challenges and Opportunities in the Management of Diffuse Large B‐Cell Lymphoma in Older Patients. The Oncologist 2020, 26: 120-132. PMID: 33230948, PMCID: PMC7873335, DOI: 10.1002/onco.13610.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaLarge B-cell lymphomaChimeric antigen receptor T-cell therapyB-cell lymphomaChemotherapy-free approachProphylactic growth factorsOlder patientsStem cell transplantationT-cell therapyClinical trialsGeriatric vulnerabilitiesRefractory settingGeriatric assessmentCell transplantationPalliative careStandard first-line treatmentGrowth factorEarly palliative careFit older patientsTolerance of treatmentUnfavorable biologic featuresUnnecessary dose reductionsFirst-line settingFirst-line treatmentFavorable toxicity profileEfficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma: A systematic review and meta-analysis
Giri S, Aryal MR, Yu H, Grimshaw A, Pathak R, Huntington SP, Dhakal B. Efficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma: A systematic review and meta-analysis. Journal Of Geriatric Oncology 2020, 11: 1285-1292. PMID: 32513568, PMCID: PMC8721742, DOI: 10.1016/j.jgo.2020.05.013.Peer-Reviewed Original ResearchConceptsTransplant-ineligible patientsMultiple myelomaTreatment optionsPhase II/IIICumulative ranking (SUCRA) probabilitiesFirst-line treatmentHematopoietic cell transplantationTerms of efficacyRandom-effects modelEfficacious regimensFrailty biomarkersFrontline regimensThalidomide maintenanceEffective regimensGeriatric assessmentLine treatmentTreatment regimensCell transplantationMeeting libraryIndividual patientsToxicity profileRegimensPatientsSystematic reviewRanking probability
2019
Cure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment.
Huntington SF. Cure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment. Hematology 2019, 2019: 252-259. PMID: 31808838, PMCID: PMC6913455, DOI: 10.1182/hematology.2019000030.Peer-Reviewed Original ResearchConceptsFirst-line treatmentClassic Hodgkin lymphomaBrentuximab vedotinNovel therapiesLarge-scale clinical trialsLarge randomized trialsHodgkin lymphoma treatmentRisk of progressionStandard cytotoxic therapiesChemotherapy cyclesDurable remissionsMultiagent chemotherapyMost patientsClinical outcomesRandomized trialsMedical oncologyCytotoxic therapyHodgkin's lymphomaLymphoma treatmentClinical trialsSelect populationIncomplete responseAlkylator chemotherapyChemotherapyAdvanced stageUtilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States
Huntington S, Soulos P, Barr P, Jacobs R, Lansigan F, Odejide O, Schwartzberg L, Davidoff A, Gross C. Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States. Blood 2019, 134: 797. DOI: 10.1182/blood-2019-122054.Peer-Reviewed Original ResearchFirst-line settingChronic lymphocytic leukemiaFlatiron Health databaseECOG performance statusFirst-line treatmentEarly discontinuationMultivariable logistic regressionPerformance statusIbrutinib discontinuationSpeakers bureauClinical trialsCLL diagnosisCLL therapyLymphocytic leukemiaHealth databasesLogistic regressionBruton tyrosine kinase inhibitorsFirst-line ibrutinibUse of ibrutinibWorse performance statusPoor performance statusRetrospective cohort studyCommunity oncology settingClinical decision support toolCommunity oncology practices
2018
Costs of relapsed diffuse large B-cell lymphoma among Medicare patients
Huntington S, Keshishian A, McGuire M, Xie L, Baser O. Costs of relapsed diffuse large B-cell lymphoma among Medicare patients. Leukemia & Lymphoma 2018, 59: 2880-2887. PMID: 29936866, DOI: 10.1080/10428194.2018.1459613.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsCost of IllnessFemaleHealth Care CostsHospitalizationHumansInsurance Claim ReviewLymphoma, Large B-Cell, DiffuseMaleMedicareNeoplasm Recurrence, LocalRetrospective StudiesTreatment OutcomeUnited StatesConceptsDiffuse large B-cell lymphomaHealth care costsLarge B-cell lymphomaFirst-line treatmentB-cell lymphomaCare costsHealth care expendituresCare expendituresHigher health care costsOffice visit costsSecond-line therapyFirst-line therapyHigher medical costsLikelihood of relapseRelapsed cohortMedicare patientsMedicare claimsMedical costsVisit costsPropensity scoreOlder adultsPatientsLymphomaTherapyTreatment
2016
Evaluating the Economic Burden and Health Care Utilization Following First-Line Therapy for Diffuse Large B-Cell Lymphoma Patients in the US Medicare Population
Huntington S, Keshishian A, Xie L, Baser O, McGuire M. Evaluating the Economic Burden and Health Care Utilization Following First-Line Therapy for Diffuse Large B-Cell Lymphoma Patients in the US Medicare Population. Blood 2016, 128: 3574. DOI: 10.1182/blood.v128.22.3574.3574.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaFirst-line therapyHealth care utilizationNon-relapse groupRelapsed diffuse large B-cell lymphomaFirst-line treatmentCare utilizationHealth care costsRelapsed cohortSTATinMED ResearchRelapsed groupMedicare beneficiariesCare costsCause health care costsHealth-care utilization analysisSignificant health care savingsHealth care resource utilizationDiffuse large B-cell lymphoma patientsHigher health care utilizationLarge B-cell lymphoma patientsB-cell lymphoma patientsOlder adultsLarge B-cell lymphomaInitial diagnosis dateNon-relapse patients